PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Negative EBIT growth while GNPX is at 24.80%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.34%
Negative operating income growth while GNPX is at 24.80%. Joel Greenblatt would press for urgent turnaround measures.
-20.40%
Negative net income growth while GNPX stands at 24.80%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-19.61%
Negative EPS growth while GNPX is at 57.19%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-20.61%
Negative diluted EPS growth while GNPX is at 57.14%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.76%
Share reduction more than 1.5x GNPX's 75.85%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Negative OCF growth while GNPX is at 23.49%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-26.42%
Negative FCF growth while GNPX is at 22.39%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Negative 10Y OCF/share CAGR while GNPX stands at 26.85%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-21838.35%
Negative 5Y OCF/share CAGR while GNPX is at 26.85%. Joel Greenblatt would question the firm’s operational model or cost structure.
2.60%
3Y OCF/share CAGR under 50% of GNPX's 26.85%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-1109485.80%
Negative 10Y net income/share CAGR while GNPX is at 58.29%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-20425.82%
Negative 5Y net income/share CAGR while GNPX is 58.29%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
78.21%
3Y net income/share CAGR 1.25-1.5x GNPX's 58.29%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
41985.76%
Positive growth while GNPX is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
3459.24%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
143.15%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-29.04%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
15.43%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
12.93%
We expand SG&A while GNPX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.